Huang et al. reported that pretreatment serum CEA level may serve as a promising biomarker guiding adjuvant chemotherapy in rectal cancer patients with ypT3N0M0 following neoadjuvant radiotherapy [17]. This evidence concerns the gene CEACAM5 and rectal cancer.